PSA: las recomendaciones actuales | 18 OCT 22

Detección del cáncer de próstata

El estado actual de la evidencia para la detección temprana del cáncer de próstata con antígeno prostático específico (PSA)
Autor/a: Sigrid V. Carlsson, Andrew J. Vickers Medical Clinics of North America - Vo104, Issue 6, Nov 2020
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.

2. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol 1979;17(2):159–63.

3. Hara M, Koyanagi Y, Inoue T, et al. [Some physico-chemical characteristics of " -seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. Nihon Hoigaku Zasshi 1971;25(4):322–4.

4. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 1973;24(2):134–44.

5. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.

6. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156–61.

7. Wang TY, Kawaguchi TP. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann Clin Lab Sci


8. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143(6):1146–52 [discussion: 1152–4].

9. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147(3 Pt 2):841–5.

10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1):7–34.

11. Hugosson J, Roobol MJ, Mansson M, et al. A 16-yr follow-up of the European Randomized Study of screening for prostate cancer. Eur Urol 2019;76(1):43–51.

12. Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian Randomized Cancer Screening Trial. BJU Int 2018;123(5):854–60.

13. Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO Trial. N Engl J Med 2016;374(18):1795–6.

14. Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010;7(4):303–11.

15. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2017;167(7):449–55.

16. Vertosick EA, Haggstrom C, Sjoberg DD, et al. Prespecified four kallikrein marker model (4Kscore) at age 50 or 60 for early detection of lethal prostate cancer in a large population-based cohort of asymptomatic men followed for 20 years. J Urol 2020;204(2):281–8.

17. Kovac E, Carlsson SV, Lilja H, et al. Association of baseline prostate-specific antigen level with long-term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. JAMA Netw Open 2020;3(1):e1919284.

Screening for Prostate Cancer 9

18. Preston MA, Gerke T, Carlsson SV, et al. Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men. Eur Urol 2019;75(3):399–407.

19. Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J Clin Oncol 2016;34(23):2705–11.

20. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521.

21. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.

22. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157(2):120–34.

23. Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 2017;14(1):26–37.

24. Kelly SP, Anderson WF, Rosenberg PS, et al. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 2018;4(1):121–7.

25. Dalela D, Sun M, Diaz M, et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses. Eur Urol Focus 2019;5(1):77–80.

26. Bandini M, Mazzone E, Preisser F, et al. Increase in the annual rate of newly diagnosed metastatic prostate cancer: a contemporary analysis of the Surveillance, Epidemiology and End Results database. Eur Urol Oncol 2018;1(4):314–20.

27. Cantor SB, Volk RJ, Cass AR, et al. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect 2002;5(2):104–13.

28. Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of screening for prostate cancer. Eur Urol 2015;68(5):885–90.

29. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostatespecific antigen screening. N Engl J Med 2012;367(7):595–605.

30. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64(6):876–92.

31. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65(6):1046–55.

32. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostatespecific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101(6):374–83.

33. Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med 2019;381(14):1378–86.

34. Klotz L. Active surveillance for low-risk prostate cancer. Curr Opin Urol 2017; 27(3):225–30.

35. Bellardita L, Villa S, Valdagni R. Living with untreated prostate cancer: predictors of quality of life. Curr Opin Urol 2014;24(3):311–7.

36. McIntosh M, Opozda MJ, Evans H, et al. A systematic review of the unmet supportive care needs of men on active surveillance for prostate cancer. Psychooncology 2019;28(12):2307–22.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023